Search

Your search keyword '"Zaucha J"' showing total 236 results

Search Constraints

Start Over You searched for: Author "Zaucha J" Remove constraint Author: "Zaucha J"
236 results on '"Zaucha J"'

Search Results

3. Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma—Polish Lymphoma Research Group Study

5. Identification of novel genetic loci for risk of multiple myeloma by functional annotation.

6. Exploring social justice in marine spatial planning : planner and stakeholder perspectives and experiences in the Baltic Sea Region

8. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin’s lymphoma patients—the Polish Lymphoma Research Group (PLRG) Observational Study

9. S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA

10. PB2203: AGEING OF LONG-TERM ALLOGENEIC HEMATOPOIETIC CELLS RECIPIENTS COMPARED TO THEIR DONORS

11. S175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM-CELL TRANSPLANT FOR MULTIPLE MYELOMA

13. Large expert-curated database for benchmarking document similarity detection in biomedical literature search

14. International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20-Positive B Cell PTLD: Clues From the PTLD-1 Trial

15. Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL).

16. CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMA

17. RADIATION FREE THERAPY OR THE INITIAL TREATMENT OF GOOD PROGNOSIS EARLY NON‐BULKY HODGKIN LYMPHOMA, DEFINED BY A LOW METABOLIC TUMOR VOLUME AND A NEGATIVE PET‐2 ‐ RAFTING TRIAL

18. In search of social sustainability in marine spatial planning : A review of scientific literature published 2005–2020

21. Large expert-curated database for benchmarking document similarity detection in biomedical literature search

27. Large expert-curated database for benchmarking document similarity detection in biomedical literature search

32. QUO VADIS: Exploring the future of shipping in the Baltic Sea

33. OFATUMUMAB WITH IVAC FOR DLBCL PATIENTS WHO FAILED R-CHOP AND WERE NOT CANDIDATES FOR HIGH-DOSE THERAPY AND ASCT - PHASE 2 TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP (PLRG-8)

34. PRIMARY BREAST DIFFUSE LARGE B-CELL LYMPHOMA. CLINICAL FEATURES AND OUTCOME IN 55 PATIENTS. POLISH LYMPHOMA RESEARCH GROUP STUDY

36. CD34 cell dose in granulocyte colony-stimulating factor–mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen–identical sibling transplantation

38. MUSES Stakeholder Workshop Report: 'Multi-use for Sustainable Blue Growth'

41. Baseline‐PET derived metrics are the most relevant factors for risk stratification in early‐stage nonbulky HL: preliminary results of the RAFTING trial.

42. BONUS BALTSPACE D2:2 : Ambitions and Realities in Baltic Sea Marine Spatial Planning and the Ecosystem Approach: Policy and Sector Coordination in Promotion of Regional Integration

43. BONUS BALTSPACE Deliverable D2.4 : MSP as a governance approach? Knowledge integration challenges in MSP in the Baltic Sea

44. BONUS Policy Brief : Challenges and Possibilities for MSP integration in the Baltic Sea

45. BONUS BALTSPACE Deliverable D1.3 : Evaluating the sustainability of governance: a proposal for evaluating marine spatial planning in the Baltic Sea

46. EXPRESSION OF PIM KINASES IN REED-STERNBERG CELLS FOSTERS IMMUNE PRIVILEGE AND TUMOR CELL SURVIVAL IN HODGKIN LYMPHOMA

47. Phase 3 trial of pixantrone plus rituximab versus gemcitabine plus rituximab in treating relapsed/refractory transplant-ineligible aggressive non-Hodgkin's lymphoma

48. Phase 2 Open-Label study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL

50. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

Catalog

Books, media, physical & digital resources